464.93
-7.06 (-1.50%)
| Previous Close | 471.99 |
| Open | 468.70 |
| Volume | 378,804 |
| Avg. Volume (3M) | 479,029 |
| Market Cap | 21,027,047,424 |
| Price / Earnings (TTM) | 17.64 |
| Price / Earnings (Forward) | 14.93 |
| Price / Sales | 7.16 |
| Price / Book | 3.04 |
| 52 Weeks Range | |
| Earnings Date | 29 Oct 2025 |
| Profit Margin | 40.44% |
| Operating Margin (TTM) | 48.19% |
| Diluted EPS (TTM) | 25.11 |
| Quarterly Revenue Growth (YOY) | 17.20% |
| Quarterly Earnings Growth (YOY) | 5.10% |
| Total Debt/Equity (MRQ) | 2.94% |
| Current Ratio (MRQ) | 5.46 |
| Operating Cash Flow (TTM) | 1.41 B |
| Levered Free Cash Flow (TTM) | 825.79 M |
| Return on Assets (TTM) | 12.93% |
| Return on Equity (TTM) | 19.94% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Drug Manufacturers - Specialty & Generic (US) | Mixed | Bullish |
| Drug Manufacturers - Specialty & Generic (Global) | Mixed | Bullish | |
| Stock | United Therapeutics Corporation | Bullish | Bullish |
AIStockmoo Score
| Analyst Consensus | 1.5 |
| Insider Activity | -3.5 |
| Price Volatility | -0.5 |
| Technical Moving Averages | 1.5 |
| Technical Oscillators | -0.5 |
| Average | -0.30 |
|
United Therapeutics Corp specializes in drug development for pulmonary arterial hypertension (PAH), a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The company's therapies for PAH largely focus on the prostacyclin pathway, and many of its treatments are based on the same molecule, treprostinil. The company markets and sells the following commercial therapies in the United States to treat PAH: Tyvaso DPI (treprostinil) Inhalation Powder, Remodulin Injection, Orenitram (treprostinil) Extended-Release Tablets, Adcirca (tadalafil) Tablets, and Unituxin. In addition, it is developing a pipeline of projects that includes new indications and delivery devices for existing products and new products to treat PAH and other conditions. |
|
| Sector | Healthcare |
| Industry | Drug Manufacturers - Specialty & Generic |
| Investment Style | Mid Core |
| % Held by Insiders | 1.75% |
| % Held by Institutions | 100.69% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Avoro Capital Advisors Llc | 30 Sep 2025 | 2,022,222 |
| Assetmark, Inc | 30 Sep 2025 | 645,908 |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 645.00 (UBS, 38.73%) | Buy |
| Median | 556.00 (19.59%) | |
| Low | 423.00 (Wells Fargo, -9.02%) | Hold |
| Average | 545.00 (17.22%) | |
| Total | 3 Buy, 1 Hold | |
| Avg. Price @ Call | 465.83 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| UBS | 06 Jan 2026 | 645.00 (38.73%) | Buy | 502.71 |
| 06 Nov 2025 | 600.00 (29.05%) | Buy | 454.00 | |
| HC Wainwright & Co. | 30 Oct 2025 | 525.00 (12.92%) | Buy | 453.53 |
| RBC Capital | 30 Oct 2025 | 587.00 (26.26%) | Buy | 453.53 |
| Wells Fargo | 30 Oct 2025 | 423.00 (-9.02%) | Hold | 453.53 |
| Name | Avg. Buy ($) | Avg. Sell ($) | Net Quantity | Net Value ($) |
|---|---|---|---|---|
| BENKOWITZ MICHAEL | - | 482.39 | -22,500 | -10,853,775 |
| MAHON PAUL A | - | 471.99 | -8,300 | -3,917,517 |
| Aggregate Net Quantity | -30,800 | |||
| Aggregate Net Value ($) | -14,771,292 | |||
| Aggregate Avg. Buy ($) | - | |||
| Aggregate Avg. Sell ($) | 477.19 | |||
| Name | Holder | Date | Type | Quantity | Price | Value ($) |
|---|---|---|---|---|---|---|
| MAHON PAUL A | Officer | 15 Jan 2026 | Automatic sell (-) | 8,300 | 471.99 | 3,917,517 |
| MAHON PAUL A | Officer | 15 Jan 2026 | Option execute | 8,300 | - | - |
| BENKOWITZ MICHAEL | Officer | 12 Jan 2026 | Automatic sell (-) | 22,500 | 482.39 | 10,853,775 |
| BENKOWITZ MICHAEL | Officer | 12 Jan 2026 | Option execute | 22,500 | - | - |
| Date | Type | Details |
|---|---|---|
| 05 Jan 2026 | Announcement | United Therapeutics Corporation to Present at the 44th Annual J.P. Morgan Healthcare Conference |
| 04 Nov 2025 | Announcement | United Therapeutics Corporation to Present at Upcoming Investor Conferences |
| 03 Nov 2025 | Announcement | United Therapeutics Corporation Announces First Transplant in EXPAND Clinical Trial of UKidney in Patients With End-Stage Renal Disease |
| 29 Oct 2025 | Announcement | United Therapeutics Corporation Reports Record Third Quarter 2025 Financial Results |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |